Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting $^{131}$I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases

Zhong-Ling Qiu, Chen-Tian Shen, Zhen-kui Sun, Wei-Jun Wei, Xin-Yun Zhang, Hong-Jun Song, Quan-Yong Luo

Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Key Words
Papillary thyroid cancer • $^{131}$I therapy • plasma LncRNAs • Lung metastases

Abstract
Purpose: The aims of the current study were to explore plasma lncRNAs as a novel biomarker panel for the diagnosis of non-$^{131}$I-avid lung metastases of PTC and to investigate the plasma lncRNA expression levels associated with survival in PTC patients with lung metastases.

Methods: The expression of lncRNAs was examined using an lncRNA microarray chip. The lncRNAs with the most significant difference in expression between PTC patients with non-$^{131}$I-avid lung metastases and PTC patients with $^{131}$I-avid lung metastases were verified by quantitative reverse-transcription polymerase chain reaction. The Kaplan–Meier method was used to determine whether the plasma lncRNA levels might be indicative of patient prognosis.

Results: Compared with $^{131}$I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 and ENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-$^{131}$I-avid lung metastases of PTC. Receiver operating characteristic curve (ROC) analyses indicated that the use of these four lncRNAs had high diagnostic sensitivity and specificity for predicting non-$^{131}$I-avid lung metastases of PTC. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels (TCONS_00024700 and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases ($P<0.001$).

Conclusions: ENST00000462717, ENST00000415582, TCONS_00024700, and NR_028494 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-$^{131}$I-avid lung metastases from PTC.

Z.-L. Qiu, C.-T. Shen and Z.-K. Sun are joint first authors and contributed equally to this work.

Quan-Yong Luo, MD Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233 (China)
Tel. 86-21-64369181, Fax 86-21-64701361, E-Mail ssphnmd@foxmail.com

© 2016 The Author(s) Published by S. Karger AG, Basel
Introduction

Thyroid cancer was one of the cancers with the most rapidly increasing prevalence in the United States between 1975 and 2012, with an estimated 62,450 new cases in 2015 [1]. Its rising incidence has also been documented in many other countries [2]. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer and accounts for 70%–90% of differentiated thyroid cancer (DTC). It typically involves an indolent tumor associated with a favorable prognosis, with ten survival rates of ~90% [3].

Metastasis to lung, the most common site of distant metastasis of DTC, is associated with a relatively poor prognosis [4]. Treatment of patients with lung metastasis is based on radioiodine (¹³¹I) and associated with levothyroxine (T4) suppression [4]. Two-thirds of lung metastasis patients have ¹³¹I uptake on a therapeutic ¹³¹I whole-body scan (¹³¹I-WBS), and a half of these achieve remission. The remaining one-third of such patients have no ¹³¹I uptake ability and die early because of ¹³¹I-refractory PTC [4, 5]. Without ¹³¹I uptake, radioiodine therapy has no obvious benefit for those with non-¹³¹I-avid metastatic lesions [6]. Such patients should not undergo unnecessary ¹³¹I treatment and can thus avoid the risk of high serum TSH stimulation after thyroxin withdrawal and the side effects of such treatment. Therefore, it is important to identify accurate predictive biomarkers in order to develop novel ¹³¹I therapeutic strategies. Specifically, promising noninvasive biomarkers to identify non-¹³¹I-avid lung metastasis of PTC prior to ¹³¹I therapy are urgently needed. Compared with sampling of tissue, blood is minimally invasive to sample and easy to obtain, making it attractive to explore potential biomarkers.

Long noncoding RNAs (lncRNAs) are RNA molecules that are longer than 200 nucleotides and not translated into proteins [7]. Although these long noncoding transcripts were once considered to be simply transcriptional "noise" or cloning artifacts [8], recent evidence has shown that lncRNAs in PTC patients play important roles in diverse biological processes, such as transcriptional regulation, cell growth, tumorigenesis, and as novel targets for PTC diagnostics and therapeutics [9-15]. Interestingly, recent studies have suggested that lncRNAs are also present in serum, plasma, and other bodily fluids [16-18], and some plasma lncRNAs have been described as candidate biomarkers [19-21].

In this study, by using both Affymetrix (CA, USA) lncRNA microarrays and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assays, we aimed to explore the genome-wide lncRNA expression profile in plasma from non-¹³¹I-avid lung metastases compared with that in ¹³¹I-avid lung metastases from PTC, and thus sought to explore plasma lncRNAs that might serve as a novel biomarker panel in the diagnosis of non-¹³¹I-avid lung metastases of PTC. We also investigated whether plasma lncRNA expression level might be associated with survival in PTC patients with lung metastases.

Materials and Methods

Patient sample preparation

Venous blood samples were obtained from PTC patients just before ¹³¹I therapy at the Nuclear Medicine Department of Shanghai Jiao Tong University-affiliated Sixth People’s Hospital, a major ¹³¹I treatment center in China. In total, 204 patients with lung metastases who had been pathologically diagnosed with PTC after total thyroidectomy with neck lymph node dissection between 2005 and 2015 were enrolled in the study. Three to five months after total thyroidectomy, each patient received an ablative dose of ¹³¹I and was put on a low iodine diet for 3–4 weeks. ¹³¹I-WBS was performed 3–5 days after the administration of ¹³¹I at a dosage of 150–200 mCi. The patients included in the study were divided into two age- and sex-matched groups: a non-¹³¹I-avid lung metastasis group (group A) and a ¹³¹I-avid lung metastasis group (group B). A post-therapy patients showing no ¹³¹I uptake on the¹³¹I-WBS (defined as a level of ¹³¹I uptake in the lung that was similar to that in the upper limbs) were assigned to group A and those with diffuse ¹³¹I uptake to group B. PTC lung metastases in the group A were diagnosed by elevated serum thyroglobulin (Tg) and lung computed tomography (CT); PTC lung metastases in group B were diagnosed by ¹³¹I-WBS, elevated serum Tg and lung CT.
RNA extraction

Blood samples collected from each patient were placed in an EDTA anticoagulant tube. The plasma was separated by centrifugation at 800 × g for 10 min at room temperature, followed by 15-min high-speed centrifugation at 10,000 × g at room temperature to completely remove cell debris. The supernatant plasma was recovered and stored at −80°C until analysis. We extracted total RNA from 600 µL of plasma using TRIzol reagent (Sigma), in accordance with the protocol of the manufacturer. RNA quantity and quality were confirmed using a Nano Drop ND-1000 spectrophotometer. RNA integrity and gDNA contamination were tested by denatured agarose gel electrophoresis.

Microarray and computational analyses

Five pairs of patients were chosen for the microarray analyses between non-131I-avid patients and 131I-avid patients. The inclusion criteria of this five pairs of patients were as following: 1) Age, sex, height, weight, the size and number of lung metastases, and Tg level (as a marker for recurrence and metastasis of PTC related to the tumor burden) were approximately similar; 2) nationality, race and the TNM staging of the primary PTC were the same; 3) no other malignant tumor history.

Specimen labeling and microarray hybridization were completed using a modified version of the Agilent One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent Technologies, Santa Clara, CA, USA). The sample preparation and microarray hybridization were performed in accordance with the manufacturer’s instructions with minor modifications. In brief, mRNA was purified from 1 µg of total RNA following the removal of rRNA using an mRNA-ONLY™ eukaryotic mRNA isolation kit (Epicentre Biotechnologies, Madison, WI, USA). Subsequently, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3′ bias using a random priming method. The labeled cRNAs were hybridized onto a Human IncRNA Array v3.0 (8×60 K; ArrayStar, Rockville, MD, USA), designed for 30,586 IncRNAs and 26,109 coding transcripts. The IncRNAs were carefully constructed using the most highly respected public transcriptome databases, including Refseq (http://www.ncbi.nlm.nih.gov/refseq/), UCSC Known Genes (http://www.biomedsearch.com/nih/UCSC-Known-Genes/16500937.html), and GENCODE (http://www.gencodegenes.org/), as well as landmark publications [22-24]. Each transcript was accurately identified by a specific exon or splice junction probe. Positive probes for housekeeping genes and negative probes were also printed onto the arrays for hybridization quality control. After washing the slides, the arrays were scanned using a G2505C scanner (Agilent Technologies Inc.), and the acquired images of the arrays were analyzed using Feature Extraction software (version 11.0.1.1; Agilent Technologies Inc.). Quantile normalization and subsequent data processing were performed using the GeneSpring GX v12.0 software package (Agilent Technologies Inc.). The microarray was performed by KangChen Bio-tech (Shanghai, China).

Validation

To validate the differentially expressed between PTC patients non-131I-avid lung metastases and PTC patients 131I-avid lung metastases, the candidates were tested by qRT-PCR in an independent cohort from the patients remaining in group A and group B after the exclusion of the samples used in the microarray assays. Total RNA was extracted and purified using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA), in accordance with the manufacturer’s instructions, and stored at −80°C. RevertAid™ First Strand cDNA Synthesis Kit (K1622; Fermentas) was used for reverse transcription. qRT-PCR was performed in the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA) using the SYBR Green RT-PCR kit (Qiagen, Hilden, Germany). All values were normalized using an internal reference (U6, for miRNAs).

Evaluation of 131I therapeutic efficacy in the 131I-avid lung metastases group

The therapeutic effects of 131I were evaluated on the basis of the size of the metastatic lung nodules using CT. Lung nodule size was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) [25]: complete response (CR), disappearance of all target lesions or any pathological lesions (target or non-target) must have a reduction in short axis to < 10 mm; partial response (PR), ≥ 30% decrease in the diameters of target lesions; progressive disease (PD), ≥ 20% increase in the diameters of target lesions combined with an absolute increase of ≥ 5 mm in the sum of diameters (the appearance of one or more new lesions was also considered progression); stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. CR, PR and SD were defined as effectiveness and PD was defined as ineffectiveness for the 131I-avid lung metastases group.
Statistical analysis

The levels of IncRNAs differentially expressed between different groups were analyzed using Student’s t-test with fold change ≥2.0 and p<0.05 considered to indicate statistical significance. Comparisons of continuous variables between groups A and B were performed using Student’s t-test, while categorical variables were analyzed using the chi-square test. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to evaluate the specificity and sensitivity of predicting non-131I-avid lung metastases. Ten-year survival rates were analyzed using the Kaplan–Meier method with the log-rank test used for comparisons between group A and B. MedCalc software version 17.0 (MedCalc, Mariakerke, Belgium) and SPSS17.0 (SPSS Inc., Chicago, IL, USA) were used for statistical analyses.

Results

Patient characteristics

The results of the analysis of clinicopathological relevance (total of 204 patients) are summarized in Table 1. Among these 204 patients, 71 were assigned to group A and 133 to group B. These two groups had no significant differences in parameters such as age and gender (p>0.05). No other distant metastatic sites were identified. A positive history of other tumors, other treatment and other subtypes of PTC were ruled out.

Microarray-based detection of plasma IncRNAs

Human lncRNA Array (version 3.0; Agilent) was applied to detect the IncRNAs derived from the plasma of five PTC patients with non-131I-avid lung metastases from group A, and five PTC patients with 131I-avid lung metastases from group B. Compared with the 131I-avid lung metastases, we found that there were 1006 IncRNAs that were upregulated (fold change ≥2.0 and P<0.05) and 705 that were downregulated (fold change ≥2.0 and P<0.05) in non-131I-avid lung metastases, as shown in Fig. 1. To screen the biomarkers for their ability to predict non-131I-avid lung metastases of PTC, fold change ≥10 and false discovery rate (FDR) <0.01 were used as the cutoff. Compared with the IncRNAs in 131I-avid lung metastases, we identified four upregulated IncRNAs and 10 downregulated ones in the non-131I-avid lung metastasis group (Fig. 2). Fourteen candidate IncRNAs were selected to be validated in 20 pairs of samples in the following training set (Table 2).

<table>
<thead>
<tr>
<th>Table 1. Clinical and demographic features of patients with non-131I-avid (group A) and 131I-avid lung metastases (group B) from PTC</th>
<th>Group A (n=71)</th>
<th>Group B (n=133)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44 (45-82)</td>
<td>73 (45-79)</td>
<td>0.330</td>
</tr>
<tr>
<td>Gender</td>
<td>27 (14-44)</td>
<td>60 (11-44)</td>
<td>0.232</td>
</tr>
<tr>
<td>Male</td>
<td>21</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>50</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>Tg level (ng/ml)</td>
<td>857 (731-1982)</td>
<td>1064 (772-1787)</td>
<td>0.562</td>
</tr>
<tr>
<td>Tp1b level (U/ml)</td>
<td>72 (10-136)</td>
<td>89 (17-104)</td>
<td>0.394</td>
</tr>
<tr>
<td>T stage</td>
<td>1</td>
<td>22</td>
<td>0.430</td>
</tr>
<tr>
<td>T2</td>
<td>31</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>31</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>11</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td>0.006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>N1a</td>
<td>31</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>N1b</td>
<td>40</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>Chest CT scan</td>
<td>Diffuse nodules</td>
<td>Diffuse nodules</td>
<td>0.119</td>
</tr>
<tr>
<td>The largest nodule size (cm)</td>
<td>52</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>≥1</td>
<td>19</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>40</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>131I uptake in lungs</td>
<td>Close to upper limbs</td>
<td>Diffuse lung uptake</td>
<td>—</td>
</tr>
</tbody>
</table>
**Table.** Significantly differently expressed lncRNAs between group A and group B as determined by microarray (fold change ≥10 and FDR<0.01)

<table>
<thead>
<tr>
<th>Seqname</th>
<th>Chromosome</th>
<th>Strand</th>
<th>Regulation (A/B)</th>
<th>Fold change</th>
<th>FDR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENST00000462717</td>
<td>chr3</td>
<td>+</td>
<td>up</td>
<td>74.0481414</td>
<td>0.005173002</td>
<td>8.02823E-06</td>
</tr>
<tr>
<td>ENST00000415582</td>
<td>chr11</td>
<td>-</td>
<td>up</td>
<td>36.3585354</td>
<td>0.005505494</td>
<td>9.74059E-06</td>
</tr>
<tr>
<td>NR_039398</td>
<td>chr2</td>
<td>+</td>
<td>up</td>
<td>11.0520831</td>
<td>0.000184118</td>
<td>4.9249E-08</td>
</tr>
<tr>
<td>ENST00000439588</td>
<td>chr22</td>
<td>+</td>
<td>down</td>
<td>10.1712302</td>
<td>0.000847474</td>
<td>5.03978E-07</td>
</tr>
<tr>
<td>ENST00000415869</td>
<td>chr3</td>
<td>-</td>
<td>down</td>
<td>268.3059597</td>
<td>0.005642146</td>
<td>1.05452E-05</td>
</tr>
<tr>
<td>TCONS_00024700</td>
<td>chr16</td>
<td>-</td>
<td>down</td>
<td>66.9496153</td>
<td>0.00017948</td>
<td>1.71981E-08</td>
</tr>
<tr>
<td>ENST00000570512</td>
<td>chr17</td>
<td>+</td>
<td>down</td>
<td>45.7143709</td>
<td>0.00325372</td>
<td>4.34269E-06</td>
</tr>
<tr>
<td>HMIincRNA294+</td>
<td>chr2</td>
<td>+</td>
<td>down</td>
<td>34.6902973</td>
<td>0.00320032</td>
<td>3.64491E-06</td>
</tr>
<tr>
<td>NR_028494</td>
<td>chr6</td>
<td>-</td>
<td>down</td>
<td>23.824772</td>
<td>0.00017948</td>
<td>2.00404E-08</td>
</tr>
<tr>
<td>chr14:94031800-94050525+</td>
<td>chr14</td>
<td>+</td>
<td>down</td>
<td>17.728456</td>
<td>0.00131868</td>
<td>8.96215E-07</td>
</tr>
<tr>
<td>ENST00000581541</td>
<td>chr18</td>
<td>-</td>
<td>down</td>
<td>14.606191</td>
<td>0.00082024</td>
<td>1.95115E-05</td>
</tr>
<tr>
<td>ENST00000507733</td>
<td>chr5</td>
<td>-</td>
<td>down</td>
<td>14.4649268</td>
<td>0.00760034</td>
<td>1.76163E-05</td>
</tr>
<tr>
<td>TCONS_00026676</td>
<td>chr18</td>
<td>-</td>
<td>down</td>
<td>11.9257492</td>
<td>0.00020405</td>
<td>6.93415E-08</td>
</tr>
<tr>
<td>ENST00000445865</td>
<td>chr2</td>
<td>-</td>
<td>down</td>
<td>11.2516248</td>
<td>0.00036433</td>
<td>1.8571E-07</td>
</tr>
</tbody>
</table>

**Fig. 1.** Volcano plot shows the variation of lncRNAs between the non-¹³¹I-avid lung metastasis group (five patients from group A) and the ¹³¹I-avid lung metastasis group (five patients from group B). The vertical blue lines correspond to 2.0-fold increases and decreases, and the blue horizontal line represents P=0.05. Thus, the red points in the plot represent the lncRNAs that were differentially expressed with statistical significance (A). Scatter plots are the normalized signal values of the samples (log2-scaled). The lncRNAs above the top green line and below the bottom green line indicate more than 2.0-fold difference of lncRNA expression between group A and group B (B). The hierarchical clustering was performed based on lncRNAs differentially expressed between group A and group B. The results from the hierarchical clustering show lncRNA expression profiles that are distinguishable between group A and group B (C).

**Fig. 2.** Column diagram of four upregulated lncRNAs and 10 downregulated lncRNAs in group A by microarray analyses (fold change ≥10 and FDR<0.01 were used as the cutoff).
Validation using training and validation sets

We further examined the differentially expressed lncRNAs by qRT-PCR in a training sample set, including 20 cases with non-131I-avid lung metastasis and 20 with 131I-avid lung metastasis (excluding the samples used in the microarray assays). As shown in Fig. 3 and 4, this generated a panel of two lncRNAs (ENST00000462717, ENST00000415582) that were significantly upregulated and three (TCONS_00024700, NR_028494, ENST00000507733)
that were significantly downregulated in samples from the non-\(^{131}\)I-avid lung metastasis group (\(p<0.05\)).

To confirm the accuracy and specificity of these five plasma IncRNAs as a potential signature for non-\(^{131}\)I-avid lung metastases, we also examined their expression levels in a larger cohort of individual samples (the remaining 46 cases from group A and 108 from group B). As shown in Fig. 5, the expression of two IncRNAs (ENST00000462717, ENST00000415582)
in the plasma of patients with non-\(^{131}\)I-avid lung metastases was significantly higher than in the \(^{131}\)I-avid lung metastases. In addition, the expression of two lncRNAs (TCONS_00024700, NR_028494) in the plasma of patients with non-\(^{131}\)I-avid lung metastases was significantly lower than in those with \(^{131}\)I-avid lung metastases (P<0.05). Throughout the multiphase testing and analysis phases, the profile of these four lncRNAs was suggested to be a potential signature for predicting non-\(^{131}\)I-avid lung metastases.

**Predictive power of four lncRNAs for the ability to concentrate \(^{131}\)I of PTC with lung metastasis**

To evaluate the predictive power of the four circulating lncRNAs for the ability to concentrate \(^{131}\)I of PTC with lung metastases, we performed statistical analysis of the levels of these four lncRNAs in 194 samples (excluding the samples used in the microarray assays). The ROC curve displays the relationship regarding sensitivity and specificity for the four lncRNAs to predict the ability to concentrate \(^{131}\)I in cases with PTC with lung metastases.

ROC analysis of TCONS_00024700 revealed an AUC of 0.975 [95% confidence interval (CI): 0.942–0.992] (Fig. 6A). The optimal cutoff for TCONS_00024700 was 34, as measured by absolute quantification by qRT-PCR, which had sensitivity of 89.4% (95% CI: 79.4%–95.6%) and specificity of 94.5% (95% CI: 89.1%–97.8%) for predicting non-\(^{131}\)I-avid lung metastases.

ROC analysis of NR_028494 revealed an AUC of 0.918 (95% CI: 0.870–0.952) (Fig. 6B). The optimal cutoff for NR_028494 was 42, as measured by absolute quantification by qRT-PCR, which had sensitivity of 81.8% (95% CI: 70.4%–90.2%) and specificity of 85.2% (95% CI: 77.8%–90.8%) for predicting non-\(^{131}\)I-avid lung metastases.

ROC analysis of ENST00000462717 revealed an AUC of 0.890 (95% CI: 0.837–0.930) (Fig. 6C). The optimal cutoff for ENST00000462717 was 432, as measured by absolute quantification by qRT-PCR, which had sensitivity of 89.4% (95% CI: 79.4%–95.6%) and specificity of 77.3% (95% CI: 69.1%–84.3%).

ROC analysis of ENST0000415582 revealed an AUC of 0.936 (95% CI: 0.892–0.966) (Fig. 6D). The optimal cutoff of ENST0000415582 was 328, as measured by absolute quantification by qRT-PCR, which had sensitivity of 90.6% (95% CI: 86.2%–93.8%) and specificity of 86.2% (95% CI: 79.8%–91.7%).
quantification by qRT-PCR, which had sensitivity of 83.3% (95% CI: 72.1%–91.4%) and specificity of 89.1% (95% CI: 82.3%–93.9%) for predicting non-$^{131}$I-avid lung metastases.

**Relationship of circulating lncRNA levels with $^{131}$I therapeutic efficacy in the $^{131}$I-avid lung metastases group**

Of the 108 lung metastases patients with $^{131}$I-avid lung metastases of PTC, 21 achieved CR (19.4%), 45 PR (41.7%), 23 SD (25.8%) and 19 had PD (17.6%). Eighty nine cases (82.4%) were effective and 19 (17.6%) were ineffective for $^{131}$I therapy. The expression of the four plasma lncRNAs were compared between two groups according to the efficacy of radioiodine therapy and the results were showed in Fig. 8. The four lncRNAs ($\text{TCONS}_00024700$, $\text{NR}_028494$, $\text{ENST00000462717}$ and $\text{ENST00000415582}$) from patients in effective group and ineffective group were not significantly differentially expressed (all $P > 0.05$).

**Relationship of circulating lncRNA levels with survival of patients with lung metastases from PTC**

Non-$^{131}$I-avid lung metastases from PTC are often associated with a worse prognosis. We confirmed that the four above mentioned plasma lncRNAs could predict the non-$^{131}$I-avid lung metastasis of PTC. To determine whether the levels of these four plasma lncRNAs might be indicative of patient prognosis, we performed a comparison of the 10-year survival

### Table. 3. Expression of four circulating lncRNAs for predicting survival in PTC patients with lung metastasis

<table>
<thead>
<tr>
<th>lncRNA</th>
<th>No. of patients</th>
<th>No. of deaths</th>
<th>Ten-year survival rate (%)</th>
<th>Log-rank value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{TCONS}_00024700$</td>
<td>&gt;34</td>
<td>128</td>
<td>34</td>
<td>73.43</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≤34</td>
<td>66</td>
<td>35</td>
<td>46.96</td>
<td></td>
</tr>
<tr>
<td>$\text{NR}_028494$</td>
<td>&gt;42</td>
<td>121</td>
<td>34</td>
<td>71.90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≤42</td>
<td>73</td>
<td>35</td>
<td>52.05</td>
<td></td>
</tr>
<tr>
<td>$\text{ENST00000462717}$</td>
<td>&gt;432</td>
<td>88</td>
<td>38</td>
<td>56.82</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≤432</td>
<td>106</td>
<td>31</td>
<td>70.75</td>
<td></td>
</tr>
<tr>
<td>$\text{ENST00000415582}$</td>
<td>&gt;328</td>
<td>78</td>
<td>33</td>
<td>57.64</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≤328</td>
<td>126</td>
<td>36</td>
<td>71.42</td>
<td></td>
</tr>
</tbody>
</table>
Kaplan–Meier analysis also showed that the 10-year survival rates of the low TCONS_00024700 and NR_028494 groups were 46.96% and 52.05%, and those of the high TCONS_00024700 and NR_028494 groups were 73.43% and 71.09%, respectively. The 10-year survival rates of the low TCONS_00024700 and NR_028494 groups were significantly different to those of the high TCONS_00024700 and NR_028494 groups, respectively (P<0.001) (Fig. 7).

Comparison of the relative expression of four plasma lncRNAs between PTC patients with lung metastases and healthy individuals

We also detected the expression level of the four lncRNAs in 20 volunteers as healthy control. The expression of the four plasma lncRNAs was compared between PTC patients with lung metastases and healthy individuals (Fig. 9). The expression of two ENST00000462717 and ENST00000415582 in the plasma of patients with lung metastases was significantly higher than those in the healthy individuals (P<0.001 and P=0.0035) and the expression of TCONS_00024700 and NR_028494 in the plasma of patients with lung metastases was significantly lower than those in the healthy individuals (P<0.001).

Discussion

At present, the primary approach to identify non-¹³¹I-avid lung metastasis depends on combining the results of ¹³¹I-WBS and serum Tg level. A valuable marker that can be used to predict the ability to concentrate radiiodine in distant metastasis is desirable for changing to a more effective therapeutic regimen that can safely avoid unnecessary radiation and the risk of high serum TSH stimulation.

As far as PTC was concerned, Yang et al. and Lan et al. analyzed lncRNA expression profile by using microarrays in PTC tissues and identified a series of novel PTC-associated
IncRNAs respectively, which lay the foundation for further investigation of IncRNAs related to PTC[26, 27]. In addition, important regulatory mechanisms of IncRNAs in the process of tumorigenesis, progression, proliferation, metastases, apoptosis and autophagy of PTC have been reported [27-32]. BRAF-activated IncRNA (BANCR) could activate autophagy [28] and inhibit tumorigenesis in PTC and its levels might be used as a novel prognostic marker [29]. PTC susceptibility candidate 3 (PTCSC3) was found to be a tumor suppressor [30]. IncRNAs (ENST00000426615 and ENST00000537266) might be important regulators of PTC cell proliferation and motility[31]. LncRNA (LOC100507661) expression was elevated in human thyroid cancer tissue and might play a critical role in thyroid carcinogenesis [32]. LncRNA (ANRIL) might reduce p15INK4B expression through inhibiting TGF-β/Smad signaling pathway, promoting invasion and metastasis of thyroid cancer cells, and the silencing of ANRIL inhibited the invasion and metastasis of thyroid cancer cells[33]. With regard to lung metastases of PTC, it was difficult to study the correlation between tissue IncRNAs and 131I uptake of lung metastases in PTC patients from the histological level. There were two main reasons as follows: (1) PTC had a favorable prognosis and lung metastases often occurred in the final stage of the PTC patient, therefore, it wasn’t easy to find the primary PTC tissue which had been removed from the initial operation [4, 5]; (2) it wasn’t convenient and had a little risk to obtain the tissue sample of lung metastatic lesions by CT-guided biopsy.

Liquid biopsy for cancer diagnosis has rapidly developed owing to its noninvasiveness and time-saving procedure [34, 35].In the last decade, studies on the utility of circulating nucleic acids such as cell-free DNA, miRNA, and mRNA as novel biomarkers for various human diseases have increased exponentially. Recently, several studies have demonstrated that certain circulating IncRNAs have potential utility as diagnostic markers for numerous cancers and other diseases [17, 20]. For example, researchers have identified that three circulating IncRNAs can predict human NSCLC through high-throughput screening [19]. However, to the best of our knowledge, circulating IncRNA profiles haven’t been analyzed and compared between non-131I-avid and 131I-avid lung metastases from PTC.

In the present study, we thus performed initial screening using microarray assays to measure IncRNA expression followed by extensive qRT-PCR validation between non-131I-avid and 131I-avid lung metastases from PTC. We identified a profile in which four IncRNAs (ENST00000462717, ENST00000415582, TCONS_000024700, and NR_028494) differed in their expression in the sera of PTC patients between non-131I-avid and 131I-avid lung metastases, including two downregulated IncRNAs (TCONS_00024700 and NR_028494) and two upregulated ones (ENST00000462717 and ENST00000415582). Our results suggest that the use of these four IncRNAs may be a potential minimally invasive biomarker for the preoperative diagnosis of PTC with relatively high sensitivity and specificity. The exosome is a possible vector of the IncRNAs in hematogenous dissemination. However, the mechanisms accounting for the stability of plasma IncRNAs are not well known; they may be protected by exosome encapsulation, as has been shown to occur for plasma miRNAs [36].

For patients with non-131I-avid pulmonary disease of PTC, the benefit of radioiodine therapy was very limited. Loss of 131I avidity is associated with a poor outcome. Several studies have reported that DTC patients with 131I avidity survive longer than those with non-131I-avid pulmonary metastasis[37, 38]. For example, previously our group showed that PTC patients with non-131I-avid disease had a 10-year survival rate of 38.1% compared with 69.2% for those with 131I-avid metastases (P<0.0001) [4]. We confirmed that the four above-mentioned plasma IncRNAs might predict the non-131I-avid lung metastasis of PTC. As such, we hypothesized that these four IncRNAs might be related to the prognosis of PTC patients with lung metastases. In view of this, we compared the 10-year survival rates between groups with low and high levels of these IncRNAs. The results confirmed that the levels of these four plasma IncRNAs were associated with the prognosis of PTC patients with lung metastases. Our study also showed that these four IncRNAs weren’t associated with the 131I therapeutic efficacy in the 131I-avid lung metastatic patients.

However, limitations of this study should also be discussed. First, in all of the eligible patients, there was no histopathological verification of the lung metastases. However,
obtaining histological proof of diffuse lesions in lungs was impractical and unethical in these patients. The diagnosis of lung metastasis in the current study was made on the basis of the presence of diffuse bilateral pulmonary nodules, as confirmed by a CT scan, and significantly increased serum Tg levels. Second, although the deregulation of the four lncRNAs in PTC patients with non-\(^{131}\)I-avid lung metastatic disease was validated by qRT-PCR, the small sample size in the present study, especially for non-\(^{131}\)I-avid lung metastases and healthy individuals, may make the final results biased. In this regard, further large-scale studies are required to determine the role of circulating lncRNAs in PTC patients with non-\(^{131}\)I-avid lung metastases of PTC.

**Conclusion**

We identified four lncRNAs, ENST00000462717, ENST00000415582, TCONS_00024700, and NR_028494, that are potential markers for predicting non-\(^{131}\)I-avid lung metastatic diseases from PTC. High levels of ENST00000462717 and ENST00000415582 and low levels of TCONS_00024700 and NR_028494 were associated with worse prognosis in PTC patients with lung metastases. These findings provide us with a foundation for the development of a simple, minimally invasive, and effective diagnostic and prognostic tool for the assessment of non-\(^{131}\)I-avid lung metastatic diseases from PTC. Long-term follow-up of the patients in the current study and a prospective study with a larger sample size are needed to further validate the usefulness of circulating lncRNAs in the diagnosis and prognostic assessment of non-\(^{131}\)I-avid lung metastatic diseases from PTC.

**Acknowledgements**

The authors thank Kang Chen Bio-tech Inc. for their support in the RNA extraction and microarray analyses.

**Funding**

This study was sponsored by the National Natural Science Foundation of China (No:81271611 & 81201115).

**Disclosure Statement**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**References**


